Assessment of cell proliferation based on group analysis of Ki-67 index in serous ovarian cancers

OBJECTIVES: Ovarian neoplasms are very important problems in medicine, because they account for 23% of all female genital neoplasms, and they are the cause of 47% deaths among women suffering from cancers of the female reproductive organs. Growth of the neoplasms depends on the speed of cells' reproduction. Monoclonal antibody Ki-67 detects specific antigen--nonhistonic protein of cellular nucleus, which is characteristic for dividing cells. It gives the possibility of using Ki-67 to establish proliferating index, especially in intensely proliferating neoplasm tissues. PURPOSE: The aim of the study was the evaluation of clinical parameters compared with histological and laboratory findings in serous carcinomas. The research analysed the level of proliferating index Ki-67 in patients with ovarian cancers and in control group. MATERIALS: The material used consisted of 41 cases of serous ovarian cancer. For clinical examinations we chose only patients who underwent primary surgical operation. The control group for Ki-67 levels were 15 patients with benign serous ovarian adenomas. METHODS: For showing Ki-67 reacting antigen in paraffin samples of ovarian cancer we used DAKO Serum (Rabbit Anti Human Ki-67 Antigen N 1574 LSAB). Tissue proliferation activity called proliferation index--IP Ki-67 was measured as a proportion of numbers of cells reacting with antigen to the total number of cells in the sample. RESULTS: Mean level of IP Ki-67 in examined group was 29.01%, compared to 5.84% in the control group and that was statistically significantly higher (p<0.05). CONCLUSIONS: The analysis of cells' proliferative activity differentiates benign adenomas from ovarian serous carcinomas. But I didn't find this kind of correlation among analysed clinical and laboratory parameters and the level of Ki-67 index in ovarian serous cancers.     

GILZ和Ki-67在上皮性卵巢癌中的表达及其临床意义研究

目的 探讨GILZ和Ki-67在上皮性卵巢癌中的表达及其临床意义。方法 采用免疫组化SP法对大连医科大学附属第二医院2006-2012年收治的12例正常卵巢组织、19例卵巢良性肿瘤组织及45例上皮性卵巢癌组织标本进行GILZ和Ki-67蛋白表达检测,分析GILZ与Ki-67之间的相关性,并进行相关临床因素分析。结果 （1）GILZ、Ki-67在上皮性卵巢癌中的表达率（57.78%,46.67%）明显高于其在正常卵巢组织和卵巢良性肿瘤组织中的表达率（0,0;0,15.79%）(P<0.05)。（2）GILZ和Ki-67的表达与年龄、组织类型、临床分期、淋巴转移、腹水及化疗疗效均无相关性（P>0.05)。（3）GILZ与Ki-67的表达呈正相关。结论 （1）GILZ和Ki-67在上皮性卵巢癌中的表达明显高于正常卵巢组织和卵巢良性肿瘤组织,提示GILZ和Ki-67在卵巢癌的发生发展中可能扮演重要角色。（2）GILZ表达的增加可导致细胞增殖的增加,其高表达水平可以作为判断卵巢癌恶性程度、病情进展的重要指标。（3）联合检测GILZ和Ki-67对肿瘤的临床诊断、治疗及预后会有一定参考价值。     

A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma

OBJECTIVES: The aim of the study was to preoperatively predict the biologic behavior of the endometrial carcinoma using immunohistochemical analysis of the p53 protein and Ki-67 expression, and estrogen receptor (ER) and progesterone receptor (PR) status, in the material obtained by fractional curettage. METHODS: One hundred and thirty-six patients with primary endometrial carcinoma were included in the study. In all 136 patients, the fractional curettage was performed before the hysterectomy, and the diagnosis of endometrial carcinoma was confirmed pathohistologically after the surgical procedure on the hysterectomy specimens. The significance of the prognostic factors was assessed using univariate and multivariate analyses. The cutoff values of the percentage of ER, PR, p53, and Ki-67 positive cells in terms of survival probability determination were obtained as the values of the highest chi-square test, using proportional-risk regression method. A multivariate Cox regression analysis was performed to estimate the influence of several clinical, pathohistologic, and immunohistochemical covariates to patients' survival. Survival curves were determined by the Kaplan-Meier product-limit method based on the most recent clinical status. RESULTS: According to the histologic type of the tumor, fractional curettage specimens revealed 111 histologically favorable types (81.6%) and 25 unfavorable types (18.4%). The data indicate that ER, PR, Ki-67, and p53 levels of the hysterectomy specimens and those of the preoperative specimens were in fairly good agreement. The patients with the most favorable tumor grade (G I) had significantly better prognosis when the percentage of p53 positive cells was less than 15%. In the group of patients with histologic grade II, the survival was affected by ER expression (more than 30% of positive cells) and p53 levels (less than 15% of positive cells). None of the parameters was predictive in the group of patients with histologic grade III. CONCLUSIONS: We found that determination of immunohistochemical parameters (ER, PR, and p53) on well-differentiated and moderately differentiated endometrial carcinoma of favorable histologic type obtained by curettage enables the recognition of the patients with favorable prognosis, who should not be treated by radical surgery.     

Ki-67、PCNA及HPV在宫颈癌和宫颈上皮内瘤变的表达及意义

目的:研究Ki-67,增殖细胞核抗原(PCNA)在早期宫颈癌(IA~IIA期高分化)、宫颈上皮内瘤变(CINI、CINII、CINIII)及慢性宫颈炎中的表达,及其与HPV感染的关系,探究3者联合应用的诊断价值。方法:应用免疫组织化学S-P法检测宫颈病变中Ki-67、PCNA抗原的表达,PCR反应检测HPV感染,结合临床病理特点分析。结果:慢性宫颈炎、CIN、宫颈鳞癌中Ki-67阳性表达率分别为33.33%、89.19%、100%。PCNA阳性表达率分别为66.67%、97.30%、100%。HPV阳性率分别是13.33%、54.05%、1000%。CINI和CINII/III中Ki-67阳性表达率分别为85.00%、94.12%;PCNA阳性表达率分别为95.00%、100.00%。HPV阳性率分别是30%、82.35%。CIN和宫颈癌中的Ki7、PCNA及HPV的阳性表达与宫颈炎相比,差异均有显著性(P<0.05)。Ki-67及PCNA过表达率在CINII/III组与CINI组间差异显著(P<0.05)。HPV阳性率在CINII/III与CINI之间差异显著(P<0.01)。Ki-67及PCNA表达与HPV感染有相关性(P<0.05)。结论:Ki-67、PCNA抗原过表达与CINII/III和早期宫颈癌显著相关。Ki-67、PCNA表达与HPV感染率相关,联合检测宫颈组织中Ki-67、PCNA的过表达及HPV感染,有助于判断细胞的增殖活性,可作为诊断早期宫颈癌和CINII/III的标记物。     

The expression of the proliferation marker Ki-67 and oestrogen and progesterone receptors in the proximal and distal fallopian tube.

Significant epithelial proliferation is identified more frequently in the fallopian tube in patients with ovarian tumours than in control patients. More extensive sampling of the fallopian tube is also associated with a more frequent identification of epithelial proliferation.We compared cellular proliferation at either end of the fallopian tube as detected with an antiserum to the Ki-67 protein. Variations in oestrogen and progesterone receptor proteins were also examined. Proliferative activity as expressed by the Ki-67 protein, and oestrogen receptor expression was greater in the proximal fallopian tube and progesterone receptor expression was greater in the distal fallopian tube. Only the difference in progesterone receptor expression was statistically significant (P =0.0431). This study indicates that variations in Ki-67, oestrogen and progesterone receptor protein expression occur at different sites in the fallopian tube. This should be taken into account when planning studies of epithelial cell proliferation in the fallopian tube in the future.     

上皮性卵巢癌中PTEN和Ki-67的表达及意义

目的探讨上皮性卵巢癌中FTEN和Ki-67的蛋白表达及意义。方法采用免疫组织化学S-P法检测了64例上皮性卵巢癌，30例卵巢良性肿瘤和20例正常卵巢组织中FTEN和Ki-67的蛋白表达。分析FTEN和Ki-67的蛋白表达及其与各种临床病理参数、预后的关系及二者的相关性。结果在上皮性卵巢癌组织中FTEN蛋白的阳性率明显低于正常卵巢组织和卵巢良性肿瘤组织。FTEN蛋白在病理分化差的G3组阳性率明显低于分化较好的G1-G2组；在临床Ⅲ～Ⅳ期组FTEN蛋白阳性率明显低于临床Ⅰ～Ⅱ期组。而Ki-67在以上各组的阳性率与FTEN蛋白阳性率相比恰好相反。FTEN和Ki-67蛋白的阳性率与年龄、组织类型均无关。在上皮性卵巢癌中，FTEN与Ki-67的蛋白表达呈负相关(r=-0．594)。患者的生存时间与FTEN蛋白阳性率呈正相关，与Ki-67阳性率呈负相关。结论FTEN蛋白在上皮性卵巢癌中表达明显低于正常及良性肿瘤组织，提示FTEN的缺失与卵巢癌的发生、发展有关；FTEN、Ki-67阳性率与上皮性卵巢癌的病理分化、临床分期和生存时间有关，提示FTEN蛋白表达的缺失和减少导致细胞增殖的增加，预示着卵巢癌的不良预后。     

Aurora B激酶在原发性上皮性卵巢癌中的表达及临床意义

目的：检测AuroraB激酶在原发性上皮性卵巢癌组织中的表达情况,探讨其在卵巢癌发生发展中的意义。方法：用免疫组织化学PV二步法测定AuroraB蛋白在卵巢癌（n：61）、良性卵巢肿瘤（n=20）及正常卵巢（n=15）组织中的表达。并对所有卵巢癌患者进行随访,探讨AuroraB表达水平的临床意义。结果：原发性上皮性卵巢癌组织中Aurora-B蛋白阳性表达率（77.05％）显著高于良性卵巢肿瘤组织（25.00％）及正常卵巢组织（6.67％）（P=0.000）。Aurora-B蛋白表达水平与临床手术分期及病理分级有关（P=0.000,P=0.017）,而与组织类型及有无淋巴结转移无关（P=0.978,P=0.795）。单变量分析结果显示,Aurora.B与原发性上皮性卵巢癌复发有关。多变量分析结果显示,Aurora-B是影响患者复发的独立因素（P=0.000）。结论：Aurora-B蛋白的过度表达与上皮性卵巢癌的预后有关,有望成为观察患者预后的指标之一。     

P16和Ki-67在宫颈上皮内瘤变组织中的表达及意义

目的研究P16和Ki-67在宫颈上皮内瘤变组织中的表达及与高危型人乳头瘤病毒(HPV)的关系和临床意义。方法应用免疫组织化学方法检测2005年9月至2007年8月间广东省人民医院40例正常宫颈组织、103例宫颈上皮内瘤变(CIN)及56例宫颈浸润癌中P16和Ki-67的表达,并采用第二代杂交捕获试验(HC-Ⅱ)检测高危型HPVDNA。结果P16和Ki-67的表达强度与CIN的严重程度分别呈正相关(P<0.01)。P16和Ki-67在CINⅡ、CINⅢ、宫颈鳞癌及腺癌中表达呈阳性至强阳性的比例,明显高于正常宫颈组织及CINⅠ,差异有统计学意义(P<0.01)。高危型HPV感染阳性率88.9%(177/199),其中正常宫颈42.5%、CINⅠ87.5%、CINⅡ与CINⅢ均100%、宫颈鳞癌98.0%、腺癌60.0%。高危型HPVDNA负荷量与P16、Ki-67的表达强度分别呈正相关(P<0.01)。结论P16和Ki-67的表达强度与CIN的严重程度以及高危型HPVDNA负荷量密切相关;P16和Ki-67可作为诊断CINⅡ及CINⅢ的重要辅助指标。     

The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients

OBJECTIVE: Considering the limited and controversial information on the significance of the cyclin-dependent kinase inhibitor p27Kip1 in ovarian cancer, we conducted a retrospective investigation to clarify the relationships of this protein to proliferation rate, clinicopathologic variables, and prognosis of epithelial ovarian tumors. METHODS: Paraffin-embedded tissue from 43 ovarian tumors of low malignant potential (LMP) and 80 primary ovarian adenocarcinomas was stained immunohistochemically for p27Kip1, Ki-67 antigen (a marker of cell proliferation), and p53 protein. Expression of these markers was correlated with clinicopathologic features and with overall survival of patients with adenocarcinomas. RESULTS: p27Kip1 levels were significantly higher in LMP tumors as well as in low-grade, early-stage, slowly proliferating adenocarcinomas and those associated with minimal residual disease (P < 0.001). Decreased p27Kip1 expression was related to poor overall survival on its own (P = 0.0304) and, when combined, to increased proliferation rate (P = 0.0232). More importantly, in multivariate analysis, p27Kip1/Ki-67 status was independently related to survival (P = 0.040) along with histologic type and FIGO stage. CONCLUSION: Decreased p27Kip1 expression is related to several clinicopathologic indicators of aggressiveness in ovarian adenocarcinomas and is a major player in cell cycle control in these neoplasms. On the contrary, deregulation of the protein does not seem to participate in the pathogenesis of LMP tumors. Furthermore, combined p27Kip1/Ki-67 expression is a better prognostic marker than expression of p27Kip1 or Ki-67 alone and supplements the prognostic information gained from traditional prognosticators.     

Expression of the proliferation marker Ki-67 and of p53 tumor protein in trophoblastic tissue of preeclamptic, HELLP, and intrauterine growth-restricted pregnancies.

The human placenta owns the biochemical machinery to proliferate throughout gestation. The aim of this study was to investigate the expression of the proliferation marker Ki-67 in trophoblastic tissue of intrauterine growth retarded (IUGR) placentas, preeclamptic, HELLP, and in normal trophoblastic tissue. Slides of paraffin-embedded trophoblastic tissue of patients with IUGR, preeclamptic patients, HELLP patients, and normal term placentas were incubated with monoclonal antibodies against Ki-67 and p53. Staining reaction was performed with the ABC reagent. Intensity of immunohistochemical reaction on the slides was analyzed using a semiquantitative score. Identification of Ki-67-expressing cells was done by immunofluorescence double staining with Ki-67 and cytokeratin antibodies. Expression of Ki-67 and p53 are significantly elevated in cytotrophoblastic cells of placentas with HELLP as investigated by immunohistochemistry and double immunofluorescence. However, preeclamptic cytotrophoblastic tissue on the other hand showed no significantly different expression intensity of Ki-67 compared with normal placental tissue controls and no changes in p53 expression compared with controls. In IUGR cytotrophoblastic cells, we found no statistically significant change in Ki-67 expression but a statistically significant down-regulation of p53. An elevated proliferation of cytotrophoblastic cells seems to be related to HELLP, and this enhanced proliferation seems to be controlled by p53.     

Immunohistochemical staining properties of PCNA, Ki-67, p53, beta-hCG and HPL in trophoblastic disease

OBJECTIVE: In this study proliferating markers PCNA (proliferating cell nuclear antigen) Ki-67 and mutation of supressor gene p53 were investigated in gestational trophoblastic disease (GTL). These markers were tested by using immunostaining with beta subunits of human chorionic gonadotropin (hCG) and human placental lactogen (HPL). MATERIAL AND METHODS: Twenty curetting samples, 20 spontaneous abortions, 16 hydatidiform moles and two choriocarcinomas were studied and compared. Hydatidiform moles were subdivided into 10 complete and six partial moles by using flow cytometry analysis. All slides were stained with PCNA, Ki-67, p53, hCG, and HPL immunohistochemically. PCNA and Ki-67 stained slides were studied quantitatively to determine the PCNA and Ki-67 index. Other slides that were stained with p53, hCG, HPL were evaluated according to staining percentage and intensity. Staining properties of all groups were compared with each other. Variance analysis and the Mann Whitney U test were used for statistical analysis. Choriocarcinomas were not included in the statistical analysis. Ki-67 and the PCNA index in two choriocarcinoma cases found 81.4% and 41%, and 44% and 64%, respectively. One case was stained in 70% with (++) intensity by p53. While both were stained in 80% with (++) intensity by hCG, one was stained in 30% field (+) intensity by HPL. RESULTS: The four groups of complete and incomplete diagnosed hydatiform moles, spontaneous abortions and retention curettage were matched in pairs and evaluated according to the PCNA index. This index showed significant differences among the groups. The differences among the Ki-67 index, p53, hCG and HPL staining properties were not statistically significant. CONCLUSION: Our findings showed that PCNA is a significant and useful marker for trophoblastic diseases and can be used as a prognostic factor.     

BRMS1和fascin基因在卵巢上皮癌中的表达及其意义

目的 :研究原发卵巢上皮癌 (POEC)中乳腺癌转移抑制基因 (BRMS1)和运动相关蛋白 (fascin)基因表达水平及其意义。方法 :用半定量逆转录聚合酶链反应 (RT PCR)技术检测 2 5份正常卵巢、15份良性卵巢上皮瘤、2 8份卵巢上皮癌及 15份卵巢癌盆、腹腔种植转移灶中BRMS1和fascin基因mRNA表达情况。结果 :(1)BRMS1基因表达 :在POEC为 0 .4 73± 0 .179,明显低于正常卵巢和良性上皮瘤组 (P <0 .0 5 ) ;在III、IV期 (晚期 )卵巢癌原发灶中的表达显著低于I、II期 (早期 ) (P =0 .0 12 ) ,在腹腔脱落细胞阳性患者卵巢癌组织中的表达明显低于阴性者 (P =0 .0 4 3) ;(2 )fascin基因表达 :在POEC为 0 .94 1±0 .2 87,明显高于良性上皮瘤的 0 .382± 0 .0 4 6(P <0 .0 0 1) ;其表达与分期有关 ,在III、IV期卵巢癌原发灶中的表达显著高于I、II期 (P =0 .0 2 ) ;(3)fascin/BRMS1的相对光密度值(ROD)比值随肿瘤转移增加。结论 :BRMS1和fascin基因表达与卵巢上皮癌转移密切相关 ,其中fascin/BRMS1的ROD比值可成为提示卵巢癌有转移的指标     

Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer

OBJECTIVE: Many studies have demonstrated that clinically evident tumor cells already carry multiple genetic alterations and further accumulation of genetic alteration causes tumor progression which plays a role in metastasis. Therefore, it could be expected that malignant potential in the metastatic site is more aggressive than that in the primary site. Using several immunohistochemical markers (p53, Ki-67, and CD44v6), we investigated an alteration of malignant potential. METHODS: We immunohistochemically examined expression of p53, Ki-67, and CD44 in primary and metastatic lesions of ovarian cancer. Fifty-six samples of primary lesions and matched metastatic sites from 56 patients with primary epithelial ovarian cancers were included in this study. RESULTS: In 16 cases (28%), the histological grade of the metastatic lesion increased. This difference was statistically significant (P = 0.0232). In 16 cases (28%), the expression of p53 increased in the metastatic lesions, in 5 pairs from negative to positive, whereas the case decrease in the metastatic lesions was only 1. This difference was statistically significant (P = 0.0046). There was no significant difference in Ki-67 labeling indices and expression of CD44v6 between the primary and matched metastatic lesions. The degree of p53 expression in the metastatic lesions significantly correlated with disease-free survival (P = 0.0482), whereas that in the primary lesions did not. Moreover, high p53 expression in the metastatic lesions significantly correlated with disease-free survival in multivariate analysis. CONCLUSIONS: The p53 expression in metastatic lesions may reflect an aggressive biologic behavior in ovarian cancer.     

Analysis of the relationship between cancer procoagulant activity and PCNA and Ki-67 expression in cases of common and cellular uterine leiomyomas

PURPOSE: Histological subtypes of uterine leiomyomas may substantially differ in their cellular biology, including the intensity of synthesis of cancer markers and expression of cell proliferation markers. The present investigation aimed to determine the activity of cancer procoagulant (CP) in subtypes of leiomyomas, including cellular leiomyomas, and to verify whether these activities correlate with immunoexpression of cell proliferation markers: the proliferating cell nuclear antigen (PCNA) and Ki-67. MATERIALS AND METHODS: Preoperative peripheral venous blood and postoperative tissue material were obtained from 24 women operated on in a tertiary referral academic department. The activity of CP in serum was measured with the use of a coagulative method according to Gordon and Benson, and in tissue homogenates with the use of a spectrophotometric method according to Colucci et al. The control serum values were obtained from 20 healthy women without any gynecological disease, and the control solid tissue values from histologically confirmed postoperative normal reproductive tissues obtained from six patients. PCNA and Ki-67 expression were determined immunohistochemically using monoclonal antibodies. RESULTS: Both the tissue and serum activity for CP was considerably higher for common leiomyomas and cellular leiomyomas than for control tissues, but did not differ significantly between the leiomyoma subtypes. Intratumor CP activity significantly correlated with PCNA expression but not with Ki-67 expression. CONCLUSIONS: Cellular leiomyomas do not differ substantially in the serum and intratumor CP activity from common leiomyomas. There is a relationship of intratumor CP activity with PCNA expression, a finding which requires further investigation.     

PCNA、P16蛋白在卵巢癌组织中的表达及其临床价值的探讨

目的：研究PCNA、P16蛋白在卵巢癌中的表达及临床价值。方法：应用免疫组化法检测89份卵巢癌组织PCNA、P16蛋白的表达。结果：PCNA表达在上皮性,中、低分化以及晚期卵巢癌中的表达显著高于非上皮性,高分化及早期卵巢癌（P＜0．05）,PCNA表达与残存癌灶大小、是否发生淋巴结转移无关（P＞0．05）。在晚期、残存癌灶≥2cm的卵巢癌中P16蛋白的表达明显低于早期、残存癌灶＜2cm者（P＜0．05）;P16蛋白表达与组织类型、组织分化、淋巴结有无转移无关（P＜0．05）。生存分析表明,PCNA、P16蛋白尚不能作为卵巢癌的独立预后因素。结论：肿瘤细胞的过度增殖在卵巢癌的发生、发展中起一定作用。P16蛋白表达的缺失与卵巢癌的进展有关。测定卵巢癌组织P16、PCNA的表达,对客观评价肿瘤的增殖状态,进行“个体化”治疗有指导价值。     

Flow cytometric measurement of ploidy and proliferation in effusions of ovarian carcinoma and their possible prognostic significance

The cellular DNA pattern of ascites and pleural effusions from 81 patients with advanced ovarian carcinoma was prospectively studied by means of flow cytometric DNA analysis. The degree of ploidy and the proportion of S-phase values were correlated to histological differentiation, to status, and to the development of disease. According to DNA indices, the cell populations distributed in the diploid to peridiploid and in the tri-to tetraploid range. Aneuploidy was more frequently associated with poor degree of differentiation, with progressive disease, and with higher proportion of cells in S phase. Thus, although patients with stable disease had a significantly larger proportion of tumors with diploid DNA content, all except four patients were dead within a median survival period of 12 months. No correlation was observed between total survival period and ploidy; however a significantly shorter survival time was noted in patients whose ascites comprised cell populations with S-phase values exceeding 15%.     

MMP-2、TIMP-2、Ki-67在库肯勃氏瘤中的表达及意义

目的 :探讨MMP 2、TIMP 2、Ki 67表达与库肯勃氏瘤病理生物学行为的关系。方法 :采用免疫组化SP法对 32例库肯勃氏瘤组织和 10例正常卵巢组织进行MMP 2、TIMP 2和Ki 67表达的检测。结果 :MMP 2、TIMP 2、Ki 67在库肯勃氏瘤组织中的表达量显著高于正常卵巢组织 (P <0 .0 1)。有合并转移的库肯勃氏瘤中MMP 2、Ki 67高于无合并转移者 (P <0 .0 5 ) ,TIMP 2低于无合并转移者 (P <0 .0 5 )。MMP 2、Ki 67与术后生存时间呈负相关 (P <0 .0 1) ,TIMP 2与术后生存时间呈正相关 (P <0 .0 1)。结论 :MMP 2、TIMP 2、Ki 67在库肯勃氏瘤发生、发展中起重要作用 ,可作为判断卵巢转移癌恶性程度、临床分期和评估预后的临床参考指标     

Survivin、caspase-3及PCNA在卵巢上皮性肿瘤中表达的临床意义

目的 探讨凋亡调控因子Survivin、半胱氨酸天门冬氨酸蛋白酶-3(caspase-3)及细胞增殖标记指数(PCNA)在卵巢上皮性肿瘤中表达的临床意义.方法 采用免疫组织化学技术,检测2006年1月至2006年12月哈尔滨医科大学第一临床医学院收治的40例卵巢上皮性癌、10例交界性卵巢上皮性肿瘤组织及10例卵巢良性上皮性肿瘤中Survivin、caspase-3和PCNA的蛋白表达,并结合临床病理特征进行分析.结果 Survivin、caspase-3在卵巢上皮性肿瘤中表达呈负相关;Survivin和PCNA的蛋白表达呈正相关;Survivin在卵巢上皮性癌中表达率72.5%(29/40),且表达水平高于卵巢良性上皮性肿瘤(0)和交界性卵巢上皮性肿瘤(40%)(P＜0.05).caspase-3在卵巢上皮性癌中表达率0.5%(2/40),且表达水平远远低于卵巢良性上皮性肿瘤和交界性卵巢上皮性肿瘤(P＜0.01).结论 Survivin可能抑制caspase-3在卵巢癌中表达,导致卵巢癌细胞增殖,凋亡受阻,肿瘤形成;Survivin基因的表达可能发生在卵巢癌恶性转化的早期;Survivin的表达与瘤细胞分化、增殖密切相关,并且其高表达可能会作为预后不良的标志;caspase-3在卵巢癌中极低表达,有望成为卵巢癌良恶鉴别新的指标.